Shaping better health
REMEDY : BNSSG referral pathways & Joint Formulary

BNSSG Adult Joint Formulary

COVID-19 rapid evidence summaries

Checked: not set yet by Next Review: not set yet

COVID-19 rapid evidence summaries

Rapid evidence summaries on the interleukin-6inhibitors, sarilumab and tocilizumab, in the treatment of adults with COVID-19 have been replaced by NICE COVID-19 rapid guideline NG191
 
Sarilumab and tocilizumab are beneficial in adults with severe COVID‑19 who have either hypoxaemia with evidence of inflammation or are in the early stages of critical illness requiring respiratory support.   Benefit from these drugs may only be seen before or soon after organ support is started, when any developing organ dysfunction may be more reversible.  

New evidence on the effectiveness of COVID-19 treatments is being published at a rapid pace. Tocilizumab is now licensed as a treatment for adult patients hospitalised due to COVID-19 who are receiving systemic corticosteroids and require supplementary oxygen or mechanical ventilation.

See the following CAS alert and Interim Clinical Commissioning Policy for details of eligibility and exclusion criteria:

CEM/CMO/2022/004

IL-6 inhibitors (tocilizumab or sarilumab) Interim Policy

 

nMABs for hospitalised patients with COVID-19

The Department of Health and Social Care has published an updated Rapid Policy Statement on use of neutralising monoclonal antibodies for treatment of COVID-19 in hospitalised patients: 

Neutralising monoclonal antibodies (Casirivimab and imdevimab (Ronapreve®) / Sotrovimab (Xevudy®)) Interim Policy

CEM/CMO/2021/023

 

Antivirals and nMABs for non-hospitalised patients with COVID-19

The Department of Health and Social Care has published an Interim Policy on use of antivirals and neutralising monoclonal antibodies for treatment of COVID-19 in non-hospitalised patients. 

The CAS alert and associated Interim Policy and a Clinical Guide is available here.